Positive and negative regulation of cellular sensitivity to anti-cancer drugs by FGF-2.
The development of resistance to chemotherapy by tumor cells remains a constant limitation to the treatment of cancer. Over the last several years, fibroblast growth factor-2 (FGF-2) has emerged as a growth factor that is capable of modifying the sensitivity of normal and tumor cells to anti-cancer drugs. FGF-2 can produce both drug resistance and drug sensitization in different cell types treated with a variety of cytotoxic agents. An understanding of the differential cellular trafficking and biological activities of the multiple FGF-2 isoforms will help in determining the circumstances under which FGF-2 acts to inhibit versus potentiate drug action. Recent advances suggest that expression of FGF-2 in tumor cells is involved with loss of response to chemotherapy in vivo. Thus, the manipulation of FGF-2 activities to increase the effectiveness of chemotherapeutic agents may have important clinical implications.
Coleman
Aaron B
AB
Division of Molecular Medicine, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA. acoleman@coh.org
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics; D025461:Feedback, Physiological / Q000187:drug effects* / Q000235:genetics*; D016222:Fibroblast Growth Factor 2 / Q000235:genetics* / Q000494:pharmacology; D006801:Humans
D000970:Antineoplastic Agents; D016222:Fibroblast Growth Factor 2